ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

FDA To Issue “Complete Response” Letters To Drug Sponsors.

July 11, 2008

Contract Authority Expiration Confuses NCI Money Bill Estimates, Which Range From $605 To $650 Million

June 21, 1974

Dugan Head ACCC, Yarbro President Elects; Amos Honored

March 18, 1983

NCI’s Problems With FDA Appear To Be Resolved With Agreement on Drug Distribution System

August 26, 1977

Stand Up To Cancer Co-Founder Laura Ziskin Dies of Complications From Breast Cancer at 61

June 17, 2011

AC To Refuse Government Help In Future Projects

November 24, 1978